Navigation Links
Delaware Chancery Court Grants Galil Medical Ltd.'s Motion for Expedited Proceeding in Suit Against Endocare
Date:6/16/2009

YOKNEAM, Israel and PLYMOUTH MEETING, Pa., June 16 /PRNewswire/ -- On June 15, 2009, the Honorable William B. Chandler III, Chancellor for the State of Delaware, granted Galil Medical Ltd.'s motion for an expedited trial in Galil's recently-filed lawsuit against Endocare, Inc., arising out of Endocare's alleged breach of the Galil/Endocare Merger Agreement. The Chancellor granted Galil's motion after oral argument, and ordered that a two-day trial would be held on July 9 and 10 in Chancery Court in Georgetown, Delaware. Chancellor Chandler further indicated that he expected to issue a judgment in the suit by July 13, 2009, the Monday following the conclusion of the scheduled trial. Under the expedited schedule, Endocare is required to submit its answer to Galil's Complaint by June 19. Moreover, the previous termination date for the Galil/Endocare Merger Agreement (June 30) now has been extended so that Galil and Endocare will have additional time to complete their planned merger once the Chancellor rules.

Galil, a global cryotherapy company, filed the suit on June 9, 2009, to enforce the merger agreement between Galil and Endocare announced in November and to enjoin the proposed acquisition of Endocare by HealthTronics, Inc.

Martin J. Emerson, President and CEO of Galil, stated that Galil welcomed the Chancellor's decision to grant Galil's motion for an expedited trial. He stated that, "Galil remains committed to resolving this case as quickly as possible, and then concluding our merger with Endocare. The merger between Galil and Endocare remains in the best interests of both companies, as well as the interests of the doctors and patients we serve."

About Galil Medical

Galil Medical develops, manufactures and markets innovative products utilizing a proprietary cryotherapy platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. Galil Medical's systems enable minimally invasive, targeted ablation of benign and cancerous tumors while ensuring rapid recovery and enhanced quality of life for patients. The Presice(TM) Cryoablation System features multi-point thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent procedure control in treating prostate and renal cancer. The SeedNet MRI(TM) system provides physicians with an easy-to-use cryoablation solution to precisely ablate tumors while protecting adjacent structures, under MRI guidance.

Galil Medical shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. and RDC Rafael Development Corporation, Ltd. For more information, please visit www.galilmedical.com.


'/>"/>
SOURCE Galil Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook
2. National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit
3. Growth in Delaware Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
4. Universal Capital Management Reports Top Delaware Surgeon to Join Advisory Board
5. Delaware Youth Shares Epilepsy Message on Capitol Hill
6. Silverman, McDonald & Friedman Opens New Office in New Castle to Serve Legal Needs of Delaware Families
7. HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference
8. U.S. District Court in Delaware Reinstates Damage Awards to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
9. AARP Survey Reveals Boomers Health Care Needs in Delaware
10. AARP Represents the Pulse of Delawareans 50+: Survey Reveals Attitudes about Health Care in Delaware
11. PA Department of Health Urges Sexually Active Individuals in Delaware County to Get STD Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... The Association of Home Care Coding & ... Health and Hospice ICD-10 Transition Workgroup are working closely with the American Hospital ... to address concerns over the use of 'A' as the seventh character indicating ...
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... , ... The schedule is now online for the largest and ... is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give ... of chronic illness in children. , Very recent articles have cited 1 child in ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Calif. , Feb. 8, 2016  HemaFlo Therapeutics, Inc. ... (USPTO) has issued US Patent Number 9,119,880 covering the use ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s founder, ... a powerful technology." --> Dale Peterson ...
(Date:2/8/2016)... Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka ... as president, Americas Operations, for Astellas US LLC, with responsibility ... America , effective April 1, 2016.  Robinson previously served ... the United States -- a role ... who is retiring in June 2016.  --> ...
(Date:2/8/2016)... 8, 2016 --> ... by Allied Market Research titled, "World Synthetic ... 2014-2020", estimates the world synthetic biology market to ... sequencing technology segment would continue to lead the ... segment, collectively, held around half of the market ...
Breaking Medicine Technology: